von Mehren M - Search Results

1

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.

Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Robinson MK, et al. Among authors: von mehren m. Br J Cancer. 2008 Nov 4;99(9):1415-25. doi: 10.1038/sj.bjc.6604700. Epub 2008 Oct 7. Br J Cancer. 2008. PMID: 18841159 Free PMC article.

2

Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.

Clark JI, Alpaugh RK, von Mehren M, Schultz J, Gralow JR, Cheever MA, Ring DB, Weiner LM. Clark JI, et al. Among authors: von mehren m. Cancer Immunol Immunother. 1997 Jul;44(5):265-72. doi: 10.1007/s002620050382. Cancer Immunol Immunother. 1997. PMID: 9247561 Free PMC article. Clinical Trial.

3

Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins.

Weiner LM, Alpaugh RK, von Mehren M. Weiner LM, et al. Among authors: von mehren m. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):190-2. doi: 10.1007/s002620050430. Cancer Immunol Immunother. 1997. PMID: 9435871 Free PMC article. Clinical Trial.

4

Recent advances in immunotherapy and monoclonal antibody treatment of cancer.

Cheng JD, Rieger PT, von Mehren M, Adams GP, Weiner LM. Cheng JD, et al. Among authors: von mehren m. Semin Oncol Nurs. 2000 Nov;16(4 Suppl 1):2-12. doi: 10.1053/sonu.2000.19775. Semin Oncol Nurs. 2000. PMID: 11151455 Review.

5

Monoclonal antibody therapy for cancer.

von Mehren M, Adams GP, Weiner LM. von Mehren M, et al. Annu Rev Med. 2003;54:343-69. doi: 10.1146/annurev.med.54.101601.152442. Epub 2001 Dec 3. Annu Rev Med. 2003. PMID: 12525678 Review.

6

Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.

von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, Borden E. von Mehren M, et al. Cancer. 2012 Feb 1;118(3):770-6. doi: 10.1002/cncr.26334. Epub 2011 Jul 12. Cancer. 2012. PMID: 21751200 Free PMC article. Clinical Trial.

7

Monoclonal antibody-based therapy.

von Mehren M, Weiner LM. von Mehren M, et al. Curr Opin Oncol. 1996 Nov;8(6):493-8. doi: 10.1097/00001622-199611000-00009. Curr Opin Oncol. 1996. PMID: 8971469 Review.

8

Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.

von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, Weiner LM. von Mehren M, et al. Clin Cancer Res. 2000 Jun;6(6):2219-28. Clin Cancer Res. 2000. PMID: 10873071 Clinical Trial.

9

The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.

von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM. von Mehren M, et al. Clin Cancer Res. 2001 May;7(5):1181-91. Clin Cancer Res. 2001. PMID: 11350882 Clinical Trial.

10

Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors.

Frolov A, Chahwan S, Ochs M, Arnoletti JP, Pan ZZ, Favorova O, Fletcher J, von Mehren M, Eisenberg B, Godwin AK. Frolov A, et al. Among authors: von mehren m. Mol Cancer Ther. 2003 Aug;2(8):699-709. Mol Cancer Ther. 2003. PMID: 12939459

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

210 results

Search Page

Filters